Early-stage
Inveready Seed Capital backs Qustodian
Qustodian, the Madrid-based media marketing business, has raised over тЌ1m of start-up funding.
FSI et al. invest €40m in Cerenis Therapeutics
The Fund for Strategic Investment (FSI) and existing investors have provided French biopharma Cerenis Therapeutics with a тЌ40m series-C round of funding.
Benelux still behind rest of Europe
Activity in the Benelux region decreased sharply in Q2 2010, making it once again the smallest market in Europe for private equity investments.
European buyout value quadruples in 2010
The value of European buyouts has quadrupled in the first half of 2010, according to the latest unquoteт Private Equity Barometer.
Longbow leads £1.7m Ambicare funding
Longbow Capital has led a ТЃ1.7m funding round in medical devices firm Ambicare Health.
Oséo backs Cerenis and Novasep with €10.7m
The French government's venture arm OsУЉo has invested тЌ10.7m in healthcare companies Cerenis Therapeutics and Groupe Novasep.
French buyouts lag behind rest of Europe
The French buyout market lagged behind its neighbours’ in Q2 2010, according to the unquote” Private Equity Barometer. However, the country saw a significant increase in growth capital and early stage deals.
UK buyout value falls 14% in Q2
UK and Irish buyout value fell 14% during the second quarter of 2010, according to figures from the latest unquoteт Private Equity Barometer.
Nordic PE activity keeps momentum
Nordic Buyout activity has more than doubled in the second quarter of 2010, according to the unquoteт Private Equity Barometer.
Internet investments: Venture banking on social networks
Social networking has enjoyed a meteoric rise in recent years and the sectorтs biggest player, Facebook, is this week set to announce it has 500 million users. However, there remain doubts over whether social networking can be profitable, but this has...
High-Tech Gründerfonds et al. invest €400,000 in Chromotek
High-Tech GrУМnderfonds and Bayern Kapital have provided biotechnology company Chromotek with тЌ400,000.
Seraphim Capital et al. invest £1.35m in Pyreos
Seraphim Capital has led a ТЃ1.35m round of funding in fabless semiconductor company Pyreos, alongside existing shareholders.
Edmond de Rothschild et al. invest €16m in Poxel
Edmond de Rothschild Investment Partners (EdRIP), CDC Entreprises and CrУЉdit Agricole Private Equity have provided biopharma Poxel with a тЌ16m series-A round of financing.
HTGF et al. in €2m evocatal series-B
Three years after receiving a round of seed finance, DУМsseldorf-based industrial biotech group evocatal GmbH has raised a тЌ2m round of early-stage funding.
Crédit Agricole PE et al. invest €7.5m in EyeTechCare
CrУЉdit Agricole PE and insurance company SHAM have provided medical devices developer EyeTechCare with a тЌ7.5m round of funding.
STING invests SEK 2m in ENCare
STING has injected SEK 2m in Swedish MedTech company ENCare.
Life sciences: testing times ahead?
Pharmaceuticals and biotechnology have fared marginally better than other sectors during the global recession, but the last two years have still been lacklustre for private equity investments in life sciences. However, with a healthy number of deals already...
Fouriertransform invests in El-Forest
Fouriertransform has invested SEK 20m through the issue of new shares in El-Forest AB.
Vækstfonden provides funding for EntomoPharm
VУІkstfonden has taken a stake in EntomoPharm for an undisclosed amount.
Vesalius and LRM back Complix
Vesalius Biocapital and LRM have backed Belgian pharmaceutical company, Complix NV.
SEB Venture Capital leads investment in Coresonic
SEB Venture Capital has invested тЌ1.5m in Swedish technology firm, Coresonic.
Avista commits $48.5m to OptiNose
US-based Avista Capital Partners has invested $48.5m in Norwegian medical company OptiNose.
Venture Capital: Corporates rev up their investments
US car giant General Motors has become the latest corporate to enter the venture fray, recently announcing it had established a $100m fund to invest in early-stage companies. Like traditional VC investors, this and other corporate funds will, no doubt,...
Truffle Capital et al. invest €4.8m in Pharnext
French biopharmaceutical company Pharnext has closed a тЌ4.8m series-A round of funding from Truffle Capital, Aurinvest Capital 2, FinanciУЈre Boscari and three individual investors.